Your browser doesn't support javascript.
Evaluation of Cell-Penetrating Peptides as Mucosal Immune Enhancers for Nasal Vaccination.
Lobaina, Yadira; Urquiza, Dioslaida; Garay, Hilda; Perera, Yasser; Yang, Ke.
  • Lobaina Y; Biomedical Research Division, Vaccine Department, Center for Genetic Engineering and Biotechnology (CIGB), 10600 Havana, Cuba.
  • Urquiza D; China-Cuba Biotechnology Joint Innovation Center (CCBJIC), Yongzhou Zhong Gu Biotechnology Co., Ltd, Lengshuitan District, Yongzhou City, 425000 Hunan Province China.
  • Garay H; Animal Facilities, Center for Genetic Engineering and Biotechnology, 10600 Havana, Cuba.
  • Perera Y; Biomedical Research Division, Peptide Synthesis Lab, Center for Genetic Engineering and Biotechnology, 10600 Havana, Cuba.
  • Yang K; Biomedical Research Division, Pharmaceutical Department, Molecular Oncology Group, Center for Genetic Engineering and Biotechnology, 10600 Havana, Cuba.
Int J Pept Res Ther ; 27(4): 2873-2882, 2021.
Article in English | MEDLINE | ID: covidwho-1471835
ABSTRACT
Cell-penetrating peptides (CPPs) have been evaluated as enhancers in drug delivery, their addition in medical formulations favors drug absorption allowing obtaining the pharmacological effect with lower doses. In vaccine formulations their inclusion has been also explored with interesting results. Currently mucosal vaccination constitutes a promising alternative with the main advantage of inducing both systemic and mucosal immune responses, which are crucial for control tumors and infections at mucosal tissues. In the present work the nasal immune-enhancing effect of four CPPs was evaluated in Balb/c mice. Animals were intranasally immunized with CPP and the recombinant hepatitis B surface protein (HBsAg) as model antigen. The antibody response in sera and mucosal tissue was measured by ELISA. The IFN-γ secretion response at spleen was also evaluated by ELISPOT and ELISA. Among the CPPs studied one novel peptide stand out by its ability to potentiate the humoral and cellular immune response against the co-administered antigen. Considering that the use of mucosal routes is a promising strategy in vaccination, which are gaining special relevance nowadays in the development of novel candidates against SARS-CoV-2 and other potential emerging respiratory virus, the searching and development of safe mucosal adjuvants constitute a current need.
Keywords

Full text: Available Collection: International databases Database: MEDLINE Type of study: Experimental Studies Topics: Vaccines Language: English Journal: Int J Pept Res Ther Year: 2021 Document Type: Article Affiliation country: S10989-021-10296-8

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Type of study: Experimental Studies Topics: Vaccines Language: English Journal: Int J Pept Res Ther Year: 2021 Document Type: Article Affiliation country: S10989-021-10296-8